Hybridge™ enables the identification of candidate molecules for the treatment of rare diseases, with the objective of “de-risk” as soon as possible by providing rapid, personalized support that creates value through the consolidation of intellectual property.
For each project, active support is provided over a three-year period, in order to propose at the end of this period a molecular pharmacological entity that is sufficiently mature to enter the clinical development phase within 18 months
The Hybridge™ program comprises three stages:
Orphania™ – Select R&D opportunity and set up exclusive licence covering a pharmacological target.
Studia™ – the experimental risk assessment phase. Built unique patients cell models and/or provide instrumental capabilities.
Leadia™ – research process accelerated with AI in MedChem and wet lab biology with the creation of intellectual property.